American Journal of Kidney Diseases
Volume 52, Issue 4 , Pages 661-671 , October 2008

Variability and Risk Factors for Kidney Disease Progression and Death Following Attainment of Stage 4 CKD in a Referred Cohort

  • Adeera Levin, MD, FRCPC

      Affiliations

    • Corresponding Author InformationAddress correspondence to Adeera Levin, MD, FRCPC, University of British Columbia, Director BC Provincial Renal Agency, 1081 Burrard St, Room 6010A, Vancouver, BC, Canada V6Z1Y8
    • ,
  • Ognjenka Djurdjev, MSc
    • ,
  • Monica Beaulieu, MD, FRCPC
    • ,
  • Lee Er, MSc

Received 14 September 2007 ,Accepted 24 June 2008.

References 

  1. Levin A. Identification of patients and risk factors in chronic kidney disease—Evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant. 2001;16(suppl 7):S57–S60
  2. US Renal Data System. USRDS 2006 Annual Data Report (The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD). Am J Kidney Dis. 2006;47(suppl 1):S47–S84
  3. Fox CS, Karson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–850
  4. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;42:677–684
  5. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 2):S1–S246
  6. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease (Modification of Diet in Renal Disease Study Group). N Engl J Med. 1994;330:877–884
  7. Sarnak MJ, Greene T, Wang X, et al. The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med. 2005;142:342–351
  8. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney Int. 2006;69:375–382
  9. Canadian Collaborative Group for the Prevention of Renal and Cardiovascular Endpoints Trial (CanPREVENT). www.can-prevent.ca/investigators.htmlAccessed August 16, 2007
  10. Tonelli M, Gill J, Pandeya S, Bohm C, Levin A, Kiberd B. Slowing the progression of chronic renal insufficiency. CMAJ. 2002;166:906–907
  11. Curtis BM, Ravani P, Malberti F, et al. The short and long term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes. Nephrol Dial Transplant. 2005;20:147–154
  12. Keane WF, Brenner BM, De Zeeuw D, Grunfeld JP. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study. Kidney Int. 2003;63:1499–1507
  13. Lewis EJ, Hunsicker LJ, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  14. UK CKD Guidelines—Guidelines for Identification, Management and Referral of Adults With Chronic Kidney Disease. www.kidney.org.uk/main/guidelines/UK_CKD_guidelinesAccessed August 16, 2007
  15. Caring for Australians With Renal Impairment (CARI) Guidelines—Evaluation of Renal Function. www.cari.org.au/guidelines.phpAccessed August 16, 2007
  16. Mendelssohn DC, Barrett BJ, Brownscombe LM, et al. Elevated levels of serum creatinine: Recommendations for management and referral. CMAJ. 1999;161:413–417
  17. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305
  18. Holland D, Lam M. Predictors of hospitalization and death among pre-dialysis patients: A retrospective cohort study. Nephrol Dial Transplant. 2000;15:650–658
  19. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863
  20. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869
  21. Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet. 1998;352:1252–1256
  22. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A, Kiberd BA. Cardiac risk factors and use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis. 2001;37:484–489
  23. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Vascular Access, Update 2006. Am J Kidney Dis. 2006;48(suppl 1):S248–S273
  24. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446–456
  25. Teng M, Wolf M, Ofstun MN, Lazarus JM, Hernan MA, Camargo CA. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol. 2005;16:1115–1125
  26. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70:1858–1865
  27. Levin A, Li YC. Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease?. Kidney Int. 2005;68:1973–1981
  28. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: A longitudinal study. Am J Kidney Dis. 2004;43:825–835
  29. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2937–2944
  30. Zuo L, Ma YC, Zhou YH, Wang M, Xu GB, Wang HY. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis. 2005;45:463–472
  31. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S. Estimation of glomerular filtration rate by the MDRD study equation modified for Japaense patients with chronic kidney disease. Clin Exp Nephrol. 2007;11:41–50

PII: S0272-6386(08)01104-9

doi: 10.1053/j.ajkd.2008.06.023

American Journal of Kidney Diseases
Volume 52, Issue 4 , Pages 661-671 , October 2008

Article Tools

* Image Usage & Resolution